Product Description
Prochlorperazine is used to treat nervous, emotional, and mental conditions (eg, schizophrenia) and non-psychotic anxiety. It is also used to control severe nausea and vomiting. This medicine should not be used to treat behavioral problems in older adult patients who have dementia. (Sourced from: https://www.mayoclinic.org/drugs-supplements/prochlorperazine-oral-route/side-effects/drg-20406263?p=1)
Mechanisms of Action: D2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Canada | Cyprus | Egypt | Finland | Hong Kong | India | Ireland | Italy | Lebanon | Malaysia | Malta | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Romania | Singapore | South Africa | Sri Lanka | Sweden | Taiwan | Ukraine | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|